| Title: |
Chordoma. Clinical characteristics, management and prognosis of a case series of 25 patients |
| Authors: |
Ferraresi V.; Nuzzo C.; Zoccali C.; Marandino F.; Vidiri A.; Salducca N.; Zeuli M.; Giannarelli D.; Cognetti F.; Biagini R. |
| Contributors: |
Ferraresi, V.; Nuzzo, C.; Zoccali, C.; Marandino, F.; Vidiri, A.; Salducca, N.; Zeuli, M.; Giannarelli, D.; Cognetti, F.; Biagini, R. |
| Publisher Information: |
BioMed Central Ltd.; CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND |
| Publication Year: |
2010 |
| Collection: |
Sapienza Università di Roma: CINECA IRIS |
| Subject Terms: |
adult; aged; bone neoplasm; chordoma; disease-free survival; female; human; male; middle aged; neoplasm metastasi; positron-emission tomography; prognosi; receptors; platelet-derived growth factor; spine; treatment outcome |
| Description: |
Background: Adequate surgery still remains the only curative treatment of chordoma. Interesting clinical data on advanced disease with molecularly targeted therapies were reported.Methods: We described the clinical outcome of a series of chordoma patients followed at Regina Elena National Cancer Centre of Rome from 2004 to 2008.Results: Twenty-five consecutive patients with sacral (11 patients), spine (13 patients), and skull base (1 patient) chordoma went to our observation. Six patients (24%) had primary disease, 14(56%) a recurrent disease, and 5(20%) a metastatic spreading. Surgery was the primary option for treatment in 22 out of 25 patients. Surgical margins were wide in 5 (23%) and intralesional in 17(77%) patients; 3 out of 4 in-house treated patients obtained wide margins. After first surgery, radiotherapy (protons or high-energy photons) were delivered to 3 patients. One out of the 5 patients with wide margins is still without evidence of disease at 20 months from surgery; 2 patients died without evidence of disease after 3 and 36 months from surgery. Sixteen out of 17 (94%) patients with intralesional margins underwent local progression at a median time of 18 months with a 2-year local progression-free survival of 47%. The 5-year metastasis-free survival rate was 78.3%. Seventeen patients with locally advanced and/or metastatic disease expressing platelet-derived growth factor receptor (PDGFR) β were treated with imatinib mesylate. A RECIST stabilization of the disease was the best response observed in all treated cases. Pain relief with reduction in analgesics use was obtained in 6 out of 11 (54%) symptomatic patients. The 5- and 10-year survival rates of the entire series of patients were 76.7 and 59.7%, respectively.Conclusions: Despite progress of surgical techniques and the results obtained with targeted therapy, more effort is needed for better disease control. Specific experience of the multidisciplinar therapeutic team is, however, essential to succeed in improving patients' outcome. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/20109225; info:eu-repo/semantics/altIdentifier/wos/WOS:000275207900001; volume:10; issue:Jan 28; firstpage:1; lastpage:10; numberofpages:10; journal:BMC CANCER; http://hdl.handle.net/11573/1310612 |
| DOI: |
10.1186/1471-2407-10-22 |
| Availability: |
http://hdl.handle.net/11573/1310612; https://doi.org/10.1186/1471-2407-10-22 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.8AE0B4E1 |
| Database: |
BASE |